2025
Glucarpidase for treatment of high-dose methotrexate toxicity
Gupta S, Kaunfer S, Chen K, Dias J, Vijayan A, Rajasekaran A, Prosek J, Truong H, Wood A, Bassil C, Renaghan A, Shah C, Zhang J, Glezerman I, Carlos C, Kelly K, Passero C, Drappatz J, Abudayyeh A, Shin D, Sperati C, Yelvington B, Kanduri S, Neyra J, Edmonston D, Shirali A, Bansal A, Geara A, Mithani Z, Ziolkowski S, Rashidi A, Jakubowski J, Pujari A, Bond D, Dotson E, Wall S, Patton J, Barreto J, Herrmann S, Sheikh M, Baz R, Lee J, Lucchesi N, Kolman M, Rasheed M, Afzal A, Kang D, Mahesh A, Hsu R, Nicolaysen A, Tefera K, Schretlen C, Miller R, Velez J, Flannery A, Aklilu A, Anand S, Chandrasekhara S, Donley V, Patel A, Ni J, Krishnamurthy S, Ali R, Yilmam O, Wells S, Ortega J, Green-Lingren O, Leaf R, Sise M, Nayak L, LaCasce A, Leung N, Leaf D. Glucarpidase for treatment of high-dose methotrexate toxicity. Blood 2025, 145: 1858-1869. PMID: 39760780, DOI: 10.1182/blood.2024026211.Peer-Reviewed Original ResearchAcute kidney injuryHigh-dose methotrexate toxicityKidney recoveryPatients treated with glucarpidaseRates of acute kidney injuryDay 7Time to deathHigh-dose methotrexateCox regression modelsGlucarpidase administrationDialysis-dependentMethotrexate toxicityMethotrexate initiationKidney injuryClinical dataGlucarpidaseCancer CenterNeutropeniaEnd pointsMethotrexatePatientsHospital dischargeOutcomesTarget trial emulation frameworkDays
2019
High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?
Kitchlu A, Shirali A. High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best? Journal Of Onco-Nephrology 2019, 3: 11-18. DOI: 10.1177/2399369319827305.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply